A Novel OGR1 (GPR68) Inhibitor Attenuates Inflammation in Murine Models of Colitis
Background and Aims: Local extracellular acidification is associated with several conditions, such as ischemia, cancer, metabolic disease, respiratory diseases, and inflammatory bowel disease (IBD). Several recent studies reported a link between IBD and a family of pH-sensing G protein-coupled recep...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2021-07-01
|
| Series: | Inflammatory Intestinal Diseases |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/517474 |
| _version_ | 1818363252270170112 |
|---|---|
| author | Cheryl de Vallière Katharina Bäbler Philipp Busenhart Marlene Schwarzfischer Chiaki Maeyashiki Cordelia Schuler Kirstin Atrott Silvia Lang Marianne R. Spalinger Michael Scharl Pedro A. Ruiz-Castro Martin Hausmann Gerhard Rogler |
| author_facet | Cheryl de Vallière Katharina Bäbler Philipp Busenhart Marlene Schwarzfischer Chiaki Maeyashiki Cordelia Schuler Kirstin Atrott Silvia Lang Marianne R. Spalinger Michael Scharl Pedro A. Ruiz-Castro Martin Hausmann Gerhard Rogler |
| author_sort | Cheryl de Vallière |
| collection | DOAJ |
| description | Background and Aims: Local extracellular acidification is associated with several conditions, such as ischemia, cancer, metabolic disease, respiratory diseases, and inflammatory bowel disease (IBD). Several recent studies reported a link between IBD and a family of pH-sensing G protein-coupled receptors. Our previous studies point to an essential role for OGR1 (GPR68) in the modulation of intestinal inflammation and fibrosis. In the current study, we evaluated the effects of a novel OGR1 inhibitor in murine models of colitis. Methods: The effects of a novel small-molecule OGR1 inhibitor were assessed in the acute and chronic dextran sulfate sodium (DSS) murine models of colitis. Macroscopic disease indicators of intestinal inflammation were evaluated, and epithelial damage and immune cell infiltration and proliferation were assessed by immunohistochemistry. Results: The OGR1 inhibitor ameliorated clinical parameters in acute and chronic DSS-induced colitis. In mice treated with the OGR1 inhibitor, endoscopy showed no thickening and normal vascularity, while fibrin was not detected. Histopathological findings revealed a decrease in severity of colonic inflammation in the OGR1 inhibitor group when compared to vehicle-DSS controls. In OGR1 inhibitor-treated mice, staining for the macrophage marker F4/80 and cellular proliferation marker Ki-67 revealed a reduction of infiltrating macrophages and slightly enhanced cell proliferation, respectively. This was accompanied by a reduction in pro-inflammatory cytokines, TNF and IL-6, and the fibrosis marker TGF-β1. Conclusion: This is the first report providing evidence that a pharmacological inhibition of OGR1 has a therapeutic effect in murine colitis models. Our data suggest that targeting proton-sensing OGR1 using specific small-molecule inhibitors may be a novel therapeutic approach for the treatment of IBD. |
| first_indexed | 2024-12-13T21:45:31Z |
| format | Article |
| id | doaj.art-9b79683e8b92491caaad15387242bfbd |
| institution | Directory Open Access Journal |
| issn | 2296-9403 2296-9365 |
| language | English |
| last_indexed | 2024-12-13T21:45:31Z |
| publishDate | 2021-07-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Inflammatory Intestinal Diseases |
| spelling | doaj.art-9b79683e8b92491caaad15387242bfbd2022-12-21T23:30:26ZengKarger PublishersInflammatory Intestinal Diseases2296-94032296-93652021-07-0111410.1159/000517474517474A Novel OGR1 (GPR68) Inhibitor Attenuates Inflammation in Murine Models of ColitisCheryl de Vallière0https://orcid.org/0000-0002-8519-4451Katharina Bäbler1Philipp Busenhart2Marlene Schwarzfischer3Chiaki Maeyashiki4Cordelia Schuler5Kirstin Atrott6Silvia Lang7Marianne R. Spalinger8Michael Scharl9Pedro A. Ruiz-Castro10https://orcid.org/0000-0001-7528-1474Martin Hausmann11Gerhard Rogler12Department of Gastroenterology and Hepatology, University Hospital Zurich, (USZ), University of Zurich, Zurich, SwitzerlandDepartment of Gastroenterology and Hepatology, University Hospital Zurich, (USZ), University of Zurich, Zurich, SwitzerlandDepartment of Gastroenterology and Hepatology, University Hospital Zurich, (USZ), University of Zurich, Zurich, SwitzerlandDepartment of Gastroenterology and Hepatology, University Hospital Zurich, (USZ), University of Zurich, Zurich, SwitzerlandDepartment of Gastroenterology and Hepatology, University Hospital Zurich, (USZ), University of Zurich, Zurich, SwitzerlandDepartment of Gastroenterology and Hepatology, University Hospital Zurich, (USZ), University of Zurich, Zurich, SwitzerlandDepartment of Gastroenterology and Hepatology, University Hospital Zurich, (USZ), University of Zurich, Zurich, SwitzerlandDepartment of Gastroenterology and Hepatology, University Hospital Zurich, (USZ), University of Zurich, Zurich, SwitzerlandDepartment of Gastroenterology and Hepatology, University Hospital Zurich, (USZ), University of Zurich, Zurich, SwitzerlandDepartment of Gastroenterology and Hepatology, University Hospital Zurich, (USZ), University of Zurich, Zurich, SwitzerlandDepartment of Gastroenterology and Hepatology, University Hospital Zurich, (USZ), University of Zurich, Zurich, SwitzerlandDepartment of Gastroenterology and Hepatology, University Hospital Zurich, (USZ), University of Zurich, Zurich, SwitzerlandDepartment of Gastroenterology and Hepatology, University Hospital Zurich, (USZ), University of Zurich, Zurich, SwitzerlandBackground and Aims: Local extracellular acidification is associated with several conditions, such as ischemia, cancer, metabolic disease, respiratory diseases, and inflammatory bowel disease (IBD). Several recent studies reported a link between IBD and a family of pH-sensing G protein-coupled receptors. Our previous studies point to an essential role for OGR1 (GPR68) in the modulation of intestinal inflammation and fibrosis. In the current study, we evaluated the effects of a novel OGR1 inhibitor in murine models of colitis. Methods: The effects of a novel small-molecule OGR1 inhibitor were assessed in the acute and chronic dextran sulfate sodium (DSS) murine models of colitis. Macroscopic disease indicators of intestinal inflammation were evaluated, and epithelial damage and immune cell infiltration and proliferation were assessed by immunohistochemistry. Results: The OGR1 inhibitor ameliorated clinical parameters in acute and chronic DSS-induced colitis. In mice treated with the OGR1 inhibitor, endoscopy showed no thickening and normal vascularity, while fibrin was not detected. Histopathological findings revealed a decrease in severity of colonic inflammation in the OGR1 inhibitor group when compared to vehicle-DSS controls. In OGR1 inhibitor-treated mice, staining for the macrophage marker F4/80 and cellular proliferation marker Ki-67 revealed a reduction of infiltrating macrophages and slightly enhanced cell proliferation, respectively. This was accompanied by a reduction in pro-inflammatory cytokines, TNF and IL-6, and the fibrosis marker TGF-β1. Conclusion: This is the first report providing evidence that a pharmacological inhibition of OGR1 has a therapeutic effect in murine colitis models. Our data suggest that targeting proton-sensing OGR1 using specific small-molecule inhibitors may be a novel therapeutic approach for the treatment of IBD.https://www.karger.com/Article/FullText/517474ovarian cancer g protein-coupled receptor 1 antagonistph-sensing g protein-coupled receptorinflammatory bowel disease |
| spellingShingle | Cheryl de Vallière Katharina Bäbler Philipp Busenhart Marlene Schwarzfischer Chiaki Maeyashiki Cordelia Schuler Kirstin Atrott Silvia Lang Marianne R. Spalinger Michael Scharl Pedro A. Ruiz-Castro Martin Hausmann Gerhard Rogler A Novel OGR1 (GPR68) Inhibitor Attenuates Inflammation in Murine Models of Colitis Inflammatory Intestinal Diseases ovarian cancer g protein-coupled receptor 1 antagonist ph-sensing g protein-coupled receptor inflammatory bowel disease |
| title | A Novel OGR1 (GPR68) Inhibitor Attenuates Inflammation in Murine Models of Colitis |
| title_full | A Novel OGR1 (GPR68) Inhibitor Attenuates Inflammation in Murine Models of Colitis |
| title_fullStr | A Novel OGR1 (GPR68) Inhibitor Attenuates Inflammation in Murine Models of Colitis |
| title_full_unstemmed | A Novel OGR1 (GPR68) Inhibitor Attenuates Inflammation in Murine Models of Colitis |
| title_short | A Novel OGR1 (GPR68) Inhibitor Attenuates Inflammation in Murine Models of Colitis |
| title_sort | novel ogr1 gpr68 inhibitor attenuates inflammation in murine models of colitis |
| topic | ovarian cancer g protein-coupled receptor 1 antagonist ph-sensing g protein-coupled receptor inflammatory bowel disease |
| url | https://www.karger.com/Article/FullText/517474 |
| work_keys_str_mv | AT cheryldevalliere anovelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT katharinababler anovelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT philippbusenhart anovelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT marleneschwarzfischer anovelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT chiakimaeyashiki anovelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT cordeliaschuler anovelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT kirstinatrott anovelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT silvialang anovelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT mariannerspalinger anovelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT michaelscharl anovelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT pedroaruizcastro anovelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT martinhausmann anovelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT gerhardrogler anovelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT cheryldevalliere novelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT katharinababler novelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT philippbusenhart novelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT marleneschwarzfischer novelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT chiakimaeyashiki novelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT cordeliaschuler novelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT kirstinatrott novelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT silvialang novelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT mariannerspalinger novelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT michaelscharl novelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT pedroaruizcastro novelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT martinhausmann novelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis AT gerhardrogler novelogr1gpr68inhibitorattenuatesinflammationinmurinemodelsofcolitis |